Compass Pathways

Compass Pathways plc is a biopharmaceutical company focused on developing potential new treatment options for serious mental health conditions. Founded in 2016, the company says its work began with a personal need to find better options for a loved one and grew into a mission to address gaps in care through clinical research. Its headquarters are in London, and its clinical research program spans sites across North America and Europe.

The company’s lead investigational program is COMP360, a proprietary synthetic formulation of psilocybin being studied for treatment-resistant depression (TRD). Compass describes COMP360 as investigational and not approved for commercial use. It is evaluated in controlled clinical trials and is intended to be administered within structured protocols under the supervision of trained healthcare professionals, rather than as an unsupervised or recreational product.

Compass also reports advancing research into COMP360 for post-traumatic stress disorder (PTSD). Its development work applies pharmaceutical research and regulatory standards, including randomized, controlled and double-blind trials, and the company publishes research in peer-reviewed journals. Compass says COMP360 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for TRD and Innovative Licensing and Access Pathway designation in the United Kingdom for the same condition. These designations do not constitute marketing approval.

The company’s work is directed toward people living with serious mental health conditions, particularly those for whom existing treatments have not provided adequate relief. Compass is a pharmaceutical developer, not a treatment provider: it does not prescribe or administer its investigational treatment directly to patients. Its clinical trials are conducted through research sites, and the company directs prospective participants to trial listings for information about eligibility and locations.

Compass says its clinical research has involved more than a thousand participants and is conducted at more than 125 sites across 13 countries in North America and Europe. The company describes its aim as developing evidence-based treatment possibilities that may offer rapid and sustained benefits, while emphasizing that its investigational treatment remains subject to clinical evaluation and regulatory review.

The company presents its working culture as purpose-driven and collaborative, grounded in rigor, integrity and care. Its stated principles include setting aside personal ego in service of a shared mission, supporting colleagues and the people served, maintaining disciplined scientific standards, and continuing to pursue new possibilities in mental health care. Compass characterizes the connection between science and humanity as central to its work.